GIST: when to seek a sarcoma center

A 52-year-old man, a maintenance technician, has an endoscopy to investigate anemia and fatigue. The exam shows a rounded lesion under the stomach lining, near the entrance of the organ, about 6 cm on the CT scan. The biopsy guided by endoscopic ultrasound suggests a gastrointestinal stromal tumor, GIST. At his city's hospital, the first proposal is to remove the entire stomach, because the lesion is in a difficult position. A cousin who works in healthcare asks whether he has already been evaluated at a sarcoma center. He had never heard of that. The scene is fictional and was written for teaching.

This text uses the case as a setting for clinical reasoning for students and health professionals. The topic is the organization of care in GIST: why a rare tumor benefits from specialized pathology, molecular testing and experienced surgery, and how the network between the local hospital and the reference center can preserve organs without losing safety. The text does not replace your country's guideline or your service's protocol. If you play the case of the day on NEXO, you will recognize the challenge: the first proposal is not necessarily the only possible one.

Key points

• GIST is a rare sarcoma, and review by a specialized pathologist often changes the diagnosis and management in sarcomas.
• Molecular testing defines sensitivity to imatinib, and some subtypes practically do not respond to it.
• GIST surgery aims for complete removal with the capsule intact, and often a limited resection is enough.
• The risk of recurrence depends on size, location, mitotic count and rupture, and guides treatment after surgery.
• Reference networks help reduce inequalities when the patient lives far from the specialized center.
• Long oral treatment requires monitoring of adherence, adverse effects and fear of recurrence.

Why a rare tumor calls for a reference center

GIST arises from the cells that coordinate the movement of the digestive tract and is one of the most common types of sarcoma, but it remains rare in the routine of a general hospital. The stomach is the most common site, with 60 to 70 out of every 100 tumors, followed by the small intestine, with 20 to 25 out of every 100, according to the review by Song and colleagues. A surgeon who operates on stomach cancer every week may see few GIST per year. The pathologist may see even fewer. This low exposure is not an individual failure; it is a consequence of rarity, and that is why several countries have organized sarcoma centers and reference networks.

In Europe, about 500 thousand people are diagnosed each year with some rare solid cancer of adulthood, and delays and unequal quality of care affect survival, according to the review by the European network EURACAN. The network was created to link local and national hospitals to centers with extensive experience, so that the patient has access to correct diagnosis and treatment at the right time, directly or through the doctor who already follows them, according to the same review.

Seeking a sarcoma center does not mean abandoning the local hospital. In most models, the center reviews the pathology, discusses the case in a specialized meeting and defines the strategy, while part of the treatment and follow-up continues close to home. For the patient in the scene, the cousin's question is exactly the one the system should ask on its own: before removing the entire stomach, has someone with experience in GIST seen this case?

When to raise the alert

Some signs indicate that the case should be discussed with a specialized center before any definitive decision.

• Diagnosis of GIST or suspected subepithelial tumor larger than 2 cm.
• Proposal of extensive surgery, such as total gastrectomy, rectal amputation or surgery of the duodenum and pancreas.
• Tumor in a difficult location, such as the esophagogastric junction, duodenum or rectum.
• Pathology report without molecular testing or with an uncertain diagnosis.
• Young patient, tumor in the stomach with several nodules or suspected hereditary syndrome.
• Tumor rupture, metastatic disease or progression during treatment.

The path to diagnosis

GIST symptoms are often vague: slow bleeding with anemia, abdominal discomfort, a feeling of fullness or no symptoms at all, when the tumor is found by chance. This lengthens the path to diagnosis. In a Dutch study of 328 patients, 43 in every 100 reported a diagnostic interval of one month or more and 20 in every 100 of three months or more, according to the analysis by van Amerongen and colleagues. Long intervals were more common in women, in small bowel tumors and in intermediate-sized tumors, according to the same study.

The same work brought a finding that matters to the whole team: 20 in every 100 patients said the journey to diagnosis harmed their well-being, and those who perceived this negative impact had worse quality of life years later, although the actual length of the interval did not correlate with quality of life, according to the analysis by van Amerongen. The experience of the path, with explanations, follow-ups and referrals, weighs as much as the number of weeks.

Access to a specialized center also depends on factors outside medicine. In a study of 415 patients with sarcoma in Spain and Portugal, lower income was associated with longer delays in diagnosis, and living in a rural area was associated with being referred to other hospitals, according to the study by Mascaró-Baselga and colleagues. Only 20 in every 100 patients knew of patient associations specific to sarcoma, according to the same survey. The text on implicit bias in diagnosis helps to think about how social and gender factors lengthen the journey.

Specialized pathology and second opinion

Under the microscope, GIST resembles other spindle cell tumors, such as leiomyomas, schwannomas and leiomyosarcomas. Immunohistochemistry for KIT, also called CD117, and for DOG1 helps to separate these possibilities, and the experienced pathologist knows when the pattern does not fit and it is necessary to go further.

Specialized review changes diagnoses often in sarcomas in general. In a prospective study by the Greek group for sarcomas and rare cancers, review by a sarcoma pathologist changed the diagnosis in 37 of 119 patients, about 31 in every 100, and this changed management in 14 in every 100 patients, according to the study by Kokkali and colleagues. Molecular tests changed the diagnosis in 26 in every 100 patients tested, according to the same study.

At six specialized institutions in Greece, Poland and Spain, high-throughput sequencing panels changed the diagnosis in about 9 in every 100 of 694 sarcoma samples, according to the analysis by Kyriazoglou and colleagues. These numbers refer to sarcomas as a whole, not only to GIST, but they show the size of the risk of proceeding with a diagnosis that was never reviewed.

The molecular test that changes treatment

Most GIST have a mutation in the KIT gene or the PDGFRA gene, and the mutation site says a lot about the response to drugs. In KIT, exon 11 is the most affected site, in about 65 in every 100 GIST, followed by exon 9, in about 10 in every 100, according to the review by Song and colleagues, which notes that the mutation site correlates with the response to treatment.

Some subtypes hardly respond to imatinib. GIST with the PDGFRA D842V mutation are resistant to imatinib and can be treated with avapritinib, according to the same review and to the updated Asian consensus. In GIST without a mutation in KIT or PDGFRA, the recommendation is to perform immunohistochemistry for SDHB or broad genetic sequencing, to identify succinate dehydrogenase deficiency or other treatable alterations, as per the review by Song.

Prescribing imatinib without knowing the mutation can mean months of adverse effects with no benefit, or an inadequate dose. The Asian consensus allows increasing the dose to 800 mg a day in exon 9 mutation, mainly after progression on the standard dose, but notes that a retrospective study showed no survival gain with 800 mg instead of 400 mg in adjuvant treatment, and calls for caution with the increase.

SDH deficiency and the family

GIST with succinate dehydrogenase deficiency forms a separate group. They usually arise in the stomach, in younger people, sometimes with several nodules, and may be linked to hereditary paraganglioma and pheochromocytoma syndromes. A review of genomic testing recommends broad germline testing in this group and proposes that everyone with SDH-deficient GIST be monitored for other related tumors, whatever the germline test result, because it is not always possible to analyze methylation and the SDHA gene in full, according to the review by Florou and colleagues. Here the referral center includes clinical genetics and, often, the patient's family.

• Immunohistochemistry for KIT and DOG1 to confirm the diagnosis.
• Testing for mutations in KIT and PDGFRA before deciding on systemic treatment.
• Immunohistochemistry for SDHB when there is no mutation in KIT or PDGFRA.
• High-throughput sequencing (NGS) in cases with no identified alteration.
• Referral to clinical genetics in SDH-deficient GIST and in young patients.

Recurrence risk and mitotic count

After surgery, the central question is the risk of the tumor coming back. Risk classifications use size, anatomical site and mitotic count, and differ considerably in how they treat tumor rupture: the 2008 modified NIH classification considers any ruptured tumor high risk, according to the review by Song.

The mitotic count looks like a technical detail, but it can change the classification. The study that served as the basis for most risk systems counted mitoses in 50 high-power fields corresponding to about 4.8 mm², while modern microscopes with a wider field make the same 50 fields correspond to about 11.9 mm², according to the review by Song and colleagues. In South Korea, about 85 in every 100 pathologists use this type of eyepiece, and counting 50 fields without adjusting the area can overestimate the risk, according to the same review. Reports that give the count by area, in mm², avoid this problem.

Risk guides adjuvant treatment. In the updated Asian consensus, three years of imatinib after resection are strongly recommended for high-risk GIST, and six years may be considered. The decision also depends on the mutation: it makes no sense to offer three years of imatinib to a tumor with D842V or SDH deficiency.

Factor	Why it matters	Who provides it
Size	Larger tumors have a higher risk of recurrence	Radiology and pathology
Site	Enters the risk tables with different ranges by organ	Endoscopy, radiology and surgery
Mitotic count	Defines risk ranges and must be done by area	Pathology
Rupture	Associated with high risk of recurrence	Surgery and pathology
Mutation	Predicts response to imatinib and guides dose	Molecular pathology

Organ-preserving surgery

GIST grows by pushing the neighboring tissues, not by infiltrating like many carcinomas. So wide margins are not necessary, and segmental or wedge resections are usually enough, according to the 2025 Asian consensus guidelines. Routine lymph node removal is not indicated, because lymph node metastasis is rare in GIST; the exception is SDH-deficient GIST, in which it is enough to selectively remove enlarged lymph nodes, according to the same guidelines.

This is the point that changes the story of the patient in the scene. A tumor near the stomach entrance, to a surgeon used to gastric carcinoma, may seem to call for a total gastrectomy. To a surgeon experienced in GIST, a local resection that preserves most of the stomach may be possible, sometimes after imatinib to reduce the size, when the mutation indicates sensitivity. The difference in the patient's life is large: eating normally, with no need for vitamin B12 replacement for life.

The laparoscopic approach is recommended for smaller GISTs in favorable locations, provided the pseudocapsule is preserved and rupture is avoided, and it may be considered for larger tumors in selected cases, according to the Asian guidelines. For gastric GISTs smaller than 2 cm with no high-risk signs, active surveillance may be an acceptable option, according to the same guidelines.

In the rectum, organ preservation is also central. In a population-based analysis in the United States with 239 patients with rectal GIST, endoscopic treatment and surgical resection had similar overall and specific survival after matching, according to the study by Ding and colleagues. It is a retrospective analysis, in which patients treated by endoscopy probably had smaller tumors, but it reinforces that, in selected cases, preserving the rectum does not appear to compromise survival.

Imatinib, adherence and dose

Imatinib is a daily tablet that can be used for years. This shifts much of the treatment to the patient's home, and with it the responsibility for adverse effects, regularity and interactions with other medications.

Exposure to the drug varies greatly from person to person. In an Italian concentration monitoring service, 63 patients with GIST had 437 samples analyzed, and 67 out of every 100 of those taking 400 mg a day had a trough concentration below the recommended target of 1100 ng/mL, according to the study by Gagno and colleagues. Women had higher exposure than men, with a median of 1114 versus 786 ng/mL, according to the same study. Blood level measurement is not available everywhere, but where it exists, it helps interpret lack of response and toxicity.

The patient's experience with the drug changes with the context. In a Dutch survey with 77 patients taking imatinib, those taking the drug as adjuvant therapy reported more adverse effects and lower satisfaction than those with metastatic disease, and about 3 in every 4 patients reported high fear of recurrence or progression, according to the study by Westerdijk and colleagues. The patient who is well after surgery and needs to take a tablet with adverse effects for three years needs to understand why, or adherence suffers.

• Explain the goal of treatment and the expected duration at the first visit.
• Review interactions with other medications and with food.
• Ask actively about swelling, nausea, diarrhea, cramps and fatigue.
• Check adherence without judgment at every visit.
• Consider blood level measurement when available and there is doubt about response or toxicity.
• Offer psychological support for fear of recurrence.

Networks, local hospital and specialized center

The most common objection to centralization is distance. Not every patient can travel to a specialized center at every stage, and requiring this can create another inequality. Network models try to solve this problem with remote slide review, multidisciplinary meetings with remote participation and a clear division of tasks.

France is the most studied example. The national NETSARC+ network offers remote access to specialized diagnosis and to the sarcoma multidisciplinary meeting. In a national cohort, overall survival of patients with sarcoma was not associated with social deprivation, distance to reference centers or geographic context, according to the study by Fayet and colleagues. The authors suggest that network organization should be considered to reduce inequalities in cancer, according to the same study.

In practice, a working network for GIST has clear roles. The local hospital raises the suspicion, performs the endoscopy and the first biopsy, and sends the material. The center reviews the pathology, performs or coordinates the molecular test and discusses the case. Complex surgery usually stays at the center, while imatinib and part of the follow-up can return closer to home, with a written plan and a contact channel for questions. The post on interprofessional clinical reasoning discusses how this division of tasks works when each professional understands the role of the others.

It is also worth including the patient in this network. Patient associations offer information and support, but are little known, as the Iberian study showed. Pointing patients to these associations is part of care, as is explaining why the case was sent to the center and what each hospital will do.

The network also protects against a common reasoning error: a decision made by the first team gains weight just for having come first. The text on retrospective bias and outcome bias shows how easy it is to judge a course of action by the outcome rather than by the quality of the decision.

How NEXO helps train this reasoning

NEXO uses fictional cases with realistic clinical presentations, with up to six clues, to train step-by-step decision making. In GIST, the skill is similar: recognizing that the first hypothesis and the first proposal must be tested against other clues, such as the mutation, the location and what the organ means for the patient's life. The text on how to train differential diagnosis with clues shows how to organize this reasoning, and the post on overdiagnosis discusses when small lesions call for surveillance rather than surgery.

The Researcher track goes deeper into the mechanisms behind the clues, the Closer profile helps you measure your own accuracy, Curator organizes case curation and Creators brings together those who produce medical content. The terms of use are at /economia.

Frequently asked questions

What is a sarcoma center?

It is a service with a team experienced in sarcomas, including specialized pathology, surgery, oncology and radiology, which discusses cases in its own meeting and is usually part of a referral network.

Do I need to move to be treated at a referral center?

Generally, no. In many models, the center reviews the case and handles the more complex steps, and part of the treatment and follow-up continues at the local hospital.

Why perform a molecular test in GIST?

Because the type of mutation predicts the response to imatinib. Some subtypes barely respond and need a different strategy.

Does every GIST in the stomach require removing the whole stomach?

No. Because GIST does not usually infiltrate and rarely spreads to lymph nodes, a limited resection with the capsule intact is often enough.

How long does imatinib last after surgery?

In high-risk tumors sensitive to the drug, the standard in European and North American guidelines is three years, with extension discussed case by case.

Can GIST be hereditary?

In a minority of cases, yes, mainly in GIST with succinate dehydrogenase deficiency. In these cases, clinical genetics should take part in care.

Final checklist

• Pathology reviewed by a sarcoma specialist, with KIT and DOG1.
• Mutation testing for KIT and PDGFRA available before systemic treatment.
• SDHB assessed in cases without mutation, and clinical genetics involved when indicated.
• Risk of recurrence calculated with mitotic count per area.
• Organ-preserving surgery options discussed in a specialized meeting.
• Imatinib plan with dose, duration, adherence and adverse effects explained.
• Division of tasks between local hospital and center recorded in writing.

Play the case of the day on NEXO and practice testing the first proposal against all the clues.

References

1. Blay JY, Casali P, Ray-Coquard I, et al. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN. Lancet Reg Health Eur. 2024. PMID 38384730.
2. Ding J, Liu L, Ye Y. Endoscopic therapy versus surgical resection for rectal gastrointestinal stromal tumors: a population-based comparative analysis of long-term survival outcomes. Discov Oncol. 2025. PMID 41085807.
3. Fayet Y, Chevreau C, Decanter G, et al. No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networks' Outcome? Cancers (Basel). 2022. PMID 35681600.
4. Florou V, Jacobs MF, Casey R, et al. A Review of Genomic Testing and SDH- Deficiency in Gastrointestinal Stromal Tumors: Getting to the GIST. Cancer Med. 2025. PMID 39927693.
5. Gagno S, Buonadonna A, Cecchin E, et al. Clinical Validity of Imatinib Therapeutic Drug Monitoring in a Real-World Italian Cohort of Gastrointestinal Stromal Tumors and the Role of Patients' Sex. Pharmaceutics. 2026. PMID 42654086.
6. Hirano H, Naito Y, Takahashi T, et al. Updated Asian consensus guidelines for the diagnosis and management of gastrointestinal stromal tumor (2025). Gastric Cancer. 2026. PMID 42455249.
7. Kokkali S, Boukovinas I, de Bree E, et al. The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers. Cancers (Basel). 2024. PMID 39001377.
8. Kyriazoglou A, Zając A, Valverde C, et al. Exploring the impact of NGS on diagnostics and treatment of sarcoma: insights from real-world data across multiple institutions in Europe. ESMO Open. 2025. PMID 40939238.
9. Mascaró-Baselga P, Navarro V, Sebio A, et al. Socioeconomic disparities in sarcoma diagnosis, expert center access, and advocacy group awareness: a multicenter study in Southern Europe. Oncologist. 2026. PMID 42704687.
10. Song IH, Ahn S, Kim HD, et al. Gastrointestinal Stromal Tumor: History, Molecular Subtypes, and Risk Stratification. J Gastric Cancer. 2026. PMID 41942355.
11. van Amerongen T, Holthuis EI, van de Wal D, et al. Patient and Tumor Factors Influencing Diagnostic Trajectories in Gastrointestinal Stromal Tumor Patients and Their Impact on Health-Related Quality of Life: A Dutch Multicenter Study. Ann Surg Oncol. 2026. PMID 42135544.
12. Westerdijk K, Steeghs N, van der Graaf WTA, et al. Quality of Life and Experiences of Patients with Gastrointestinal Stromal Tumors (GIST) on Imatinib Treatment. J Gastrointest Cancer. 2026. PMID 41806031.